![These highlights do not include all the information needed to use NEXLETOL® safely and effectively. See full prescribing information for NEXLETOL. NEXLETOL (bempedoic acid) tablets, for oral use Initial U.S. Approval: 2020 These highlights do not include all the information needed to use NEXLETOL® safely and effectively. See full prescribing information for NEXLETOL. NEXLETOL (bempedoic acid) tablets, for oral use Initial U.S. Approval: 2020](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=nexletol-03.jpg&id=731861)
These highlights do not include all the information needed to use NEXLETOL® safely and effectively. See full prescribing information for NEXLETOL. NEXLETOL (bempedoic acid) tablets, for oral use Initial U.S. Approval: 2020
![Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL (bempedoic acid) Meets Primary Endpoint | DAIC Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL (bempedoic acid) Meets Primary Endpoint | DAIC](https://www.dicardiology.com/sites/default/files/styles/content_feed_large_new/public/Nexletol.jpeg?itok=GZgOJW5h)
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL (bempedoic acid) Meets Primary Endpoint | DAIC
![Landmark CLEAR Outcomes Study Demonstrates NEXLETOL (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population | DAIC Landmark CLEAR Outcomes Study Demonstrates NEXLETOL (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population | DAIC](http://www.dicardiology.com/sites/default/files/Nexletol_1.jpeg)
Landmark CLEAR Outcomes Study Demonstrates NEXLETOL (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population | DAIC
![Bempedoic acid use for statin-intolerant patients reduces incidence of MACE - Hospital Pharmacy EuropeHospital Pharmacy Europe Bempedoic acid use for statin-intolerant patients reduces incidence of MACE - Hospital Pharmacy EuropeHospital Pharmacy Europe](https://hospitalpharmacyeurope.com/wp-content/uploads/2023/04/Bempedoic-acid-use-for-statin-intolerant-patients-reduces-incidence-of-MACE.jpg)